Login / Signup

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation.

Kana WatanabeRyota SaitoEisaku MiyauchiHiromi NagashimaAtsushi NakamuraShunichi SugawaraNobuyuki TanakaHiroshi TerasakiTatsuro FukuharaMakoto Maemondo
Published in: Cancers (2023)
Plasma EGFR mutation analysis was effective in predicting the effect of osimertinib treatment.
Keyphrases
  • small cell lung cancer
  • epidermal growth factor receptor
  • advanced non small cell lung cancer
  • tyrosine kinase
  • combination therapy
  • brain metastases
  • replacement therapy